Bioventus Inc.

Bioventus Inc. (BVS) Stock Analysis

$13.840

+0.050 (+0.36%)At close

Loading chart…
High
13.965
Open
13.840
VWAP
13.84
Vol
445.70K
Mkt Cap
365.09M
Low
13.725
Amount
6.17M
EV/EBITDA, TTM
9.47

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

AI analysis of Bioventus Inc. (BVS)

buy

Bioventus Inc is a good buy right now due to its current price of $13.84 being significantly lower than the analyst price target of $18, indicating a potential upside of 30.4%. Additionally, the company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +91.96%, suggesting robust growth. The main risk is the recent 5-day change of -3.76%, indicating short-term volatility.

Valuation Metrics

The current forward P/E ratio for Bioventus Inc. (BVS) is 17.79, compared to its 5-year average forward P/E of 21.55.

Forward P/E

Fair
5Y Average P/E
21.55
Current P/E
17.79
Overvalued
53.16
Undervalued
-10.06

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
8.79
Current EV/EBITDA
9.47
Overvalued
10.90
Undervalued
6.69

Forward P/S

Overvalued
5Y Average P/S
0.87
Current P/S
1.46
Overvalued
1.27
Undervalued
0.46

Alphio AI Price Scenarios for BVS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BVS

$7.26

Scenario price

B

Base

Base · 50%BVS

$5.98

Scenario price

B

Bear

Bear · 25%BVS

$5.88

Scenario price

Whales holding BVS

N

Nantahala Capital Management, LLC

+ HoldingBVS

+9.23%

3M Return

M

Macquarie Investment Management Limited

+ HoldingBVS

+4.66%

3M Return

M

Macquarie Investment Management Global Limited

+ HoldingBVS

+2.96%

3M Return

Events Timeline

2026-08-05 (ET)

08:30:00

Bioventus Initiates Review of Strategic Alternatives

2026-06-30 (ET)

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-05-06 (ET)

08:10:00

Bioventus Q1 Revenue $132.09M, Exceeds Expectations

08:10:00

Bioventus Raises FY26 Revenue Guidance to $600M

2026-03-05 (ET)

07:20:00

Sees FY26 Revenue of $600M-$610M

News

BVS FAQ — answered by Alphio AI

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc is a good buy right now due to its current price of $13.84 being significantly lower than the analyst price target of $18, indicating a potential upside of 30.4%. Additionally, the company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +91.96%, suggesting robust growth. The main risk is the recent 5-day change of -3.76%, indicating short-term volatility.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started